Clinical Trial Update: A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating MK0822 for reducing bone metastasis risk in women with breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MK0822

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer | Phase 3 | Status: WITHDRAWN